Cannabis Stocks Dive

Advocates accuse Drug Enforcement Administration of blocking the reclassification of cannabis as a Schedule III drug under the Controlled Substances Act.
Alexander Malyshev and Sarah Ganley of Carter Ledyard & Milburn LLP discuss what the cannabis sector can expect as 2025 ...
The DEA rejected a September request from Colorado officials to participate in the United States' historic marijuana ...
Attorneys for a cannabis company and advocacy group that are set to testify in the Drug Enforcement Administration’s (DEA) marijuana rescheduling hearing process beginning this month say new evidence ...
A group of pro-cannabis entities scheduled to present in the forthcoming cannabis rescheduling hearing have filed a new ...
Despite legalization disappointments from 2024, the cannabis industry is far from standing still as the calendar changes over ...
Amplify ETFs plans to liquidate MJUS, a cannabis-related ETF, due to regulatory issues. Other cannabis ETFs also struggling ...
Here are our cannabis industry predictions for 2025: The process to reclassify marijuana as a Schedule 3 drug must end ...